A Review on Unlocking the Theraputic Potential Effects of Semaglutide in Type 2 Diabetes and Obesity

Abstract

The escalating prevalence of obesity and Type 2 Diabetes Mellitus posess a significant public health concern, necessitating innovative therapeutic strategies, mitigate complications and socioeconomic burdens. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has emerged as a transformative agent in the management of type 2 diabetes mellitus (T2DM) and obesity. Originally developed to improve glycemic control in T2DM, semaglutide has demonstrated significant benefits that extend beyond glucose regulation. Its mechanism of action involves enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite, collectively contributing to improved metabolic outcomes and substantial weight loss. Clinical trials have consistently shown that semaglutide not only lowers HbA1c levels but also facilitates meaningful reductions in body weight, positioning it as a dual-benefit therapy. Additionally, its cardiovascular safety profile and once-weekly administration improve patient adherence and quality of life. This review explores the pharmacological properties, clinical efficacy, safety considerations, and future prospects of semaglutide in managing T2DM and obesity. The growing body of evidence supports semaglutide’s role as a cornerstone in the therapeutic landscape of metabolic disorders, offering a promising strategy for addressing the global burden of diabetes and obesity.

Keywords

Introduction

Type 2 diabetes and obesity have become two of the most serious health concerns facing the global population today. Their numbers have risen dramatically over recent decades, reaching levels that are now considered epidemic. In 2021, the World Health Organization reported that more than 537 million adults were living with diabetes worldwide, the vast majority with type 2 diabetes. At the same time, rates of obesity have surged nearly tripling since 1975 now affecting over a billion people across all age groups, including children. These two conditions often go hand in hand, driven by shared risk factors like physical inactivity, poor dietary habits, and genetic influences. When they occur together, they significantly raise the risk of serious complications such as heart disease, kidney problems, and some forms of cancer. Considering the health and financial burdens linked to obesity, successful weight management is essential to reduce related illness and death ^[1].

The growing impact of type 2 diabetes and obesity is placing increasing pressure on healthcare systems and affecting the well-being of individuals and communities around the world. In light of this, there is an urgent need to find more effective ways to prevent and manage these conditions ^[2]. This review will delve into the close relationship between type 2 diabetes and obesity, while also exploring promising new treatments, particularly focusing on drugs like semaglutide.

Given the strong link between type 2 diabetes and obesity, there is a growing need for integrated treatment strategies that address both conditions simultaneously. Traditional approaches that treat them separately may overlook their shared biological pathways and risk factors ^[3]. A combined approach can lead to better outcomes by targeting the root causes, such as insulin resistance, inflammation, and excess weight. Integrating lifestyle modifications with medications that offer dual benefits like improving blood sugar control while promoting weight loss can enhance treatment effectiveness and improve long-term health for patients struggling with both conditions ^[4].

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained significant attention for its dual role in managing type 2 diabetes and obesity. Originally developed to improve glycemic control in people with type 2 diabetes, and also demonstrated notable effects on weight reduction ^[5]. It works by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. These combined actions not only help regulate blood sugar levels but also support meaningful and sustained weight loss, making semaglutide a promising therapeutic option for individuals dealing with both conditions.

CLINICAL UTILITY OF SEMAGLUTIDE

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that closely resembles the naturally occurring GLP-1 hormone involved in glucose homeostasis. It enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner, helping to lower blood glucose levels. Additionally, it delays gastric emptying and influences appetite-regulating pathways in the brain, which contributes to reduced caloric intake and weight loss ^[6]. These mechanisms make semaglutide effective in managing both type 2 diabetes and obesity. It is available in subcutaneous (once weekly) and oral (once daily) formulations. With a half-life of approximately 160–168 hours (7 days), semaglutide reaches peak plasma levels within 1–3 days after subcutaneous administration and is metabolized through proteolytic degradation and beta-oxidation. Its prolonged action, predictable pharmacokinetics, and dual metabolic benefits support its use as a convenient and potent therapeutic agent in long-term disease management ^[7].

ROLE OF SEMAGLUTIDE IN GLYCEMIC CONTROL AND TYPE 2 DIABETES

Semaglutide has demonstrated significant efficacy in lowering glycated hemoglobin (HbA1c) levels in individuals with type 2 diabetes. Clinical trials, such as the SUSTAIN and PIONEER programs, have shown that semaglutide can reduce HbA1c levels depending on the dose and baseline glycemic status. This improvement in glycemic control is primarily attributed to enhanced insulin secretion, suppressed glucagon release, and delayed gastric emptying. SUSTAIN (once-weekly subcutaneous semaglutide 1.0?mg) consistently yielded HbA1c reductions of 1.5–1.8% over 30–56 weeks superior to comparators including sitagliptin, dulaglutide, insulin glargine, liraglutide, exenatide ER, and canagliflozin ^[8]. PIONEER (daily oral semaglutide 14?mg) achieved HbA1c drops of 1.0–1.4% at 26 weeks outperforming sitagliptin and empagliflozin, and matching liraglutide’s efficacy. Both trials demonstrated that semaglutide enables a higher proportion of patients to reach target glycemic levels (<7% HbA1c) compared to other treatments ^[9].

1. COMPARISON WITH OTHER ANTIDIABETICS

Semaglutide has consistently demonstrated superior glucose-lowering efficacy when compared to several other antidiabetic medications. In head-to-head clinical trials, it has significantly outperformed DPP-4 inhibitors such as sitagliptin, leading to greater reductions in glycated hemoglobin (HbA1c) as well as more substantial weight loss. Furthermore, when evaluated against many SGLT-2 inhibitors, semaglutide has produced more pronounced improvements in both glycemic control and body weight ^[10,11]. Its efficacy also surpasses that of several other GLP-1 receptor agonists, including exenatide and dulaglutide, particularly at higher doses. These findings highlight semaglutide's robust therapeutic potential and support its preferential use in patients requiring intensive glucose lowering alongside weight management.Additionally, semaglutide carries a low risk of hypoglycemia, especially when not used in combination with sulfonylureas or insulin, making it a favorable choice for many patients ^[12].

2. ROLE IN REDUCING INSULIN RESISTANCE

Semaglutide’s glucose-lowering effects are not limited to its direct actions on pancreatic hormone regulation. In addition to enhancing glucose-dependent insulin secretion and suppressing inappropriate glucagon release, semaglutide also plays a significant role in improving overall insulin sensitivity. This improvement is largely attributed to its ability to induce meaningful and sustained weight loss, particularly through the reduction of visceral fat a key driver of insulin resistance ^[13]. Excess visceral adiposity contributes to chronic low-grade inflammation and metabolic dysfunction, both of which impair insulin signaling pathways in peripheral tissues such as muscle and liver. By decreasing fat mass, especially around abdominal organs, semaglutide helps reduce these metabolic disturbances, thereby enhancing the body’s responsiveness to insulin. As a result, patients not only achieve better glycemic control through direct hormonal modulation but also benefit from improved insulin efficiency, making semaglutide a comprehensive therapeutic option in the management of type 2 diabetes.

ROLE OF SEMAGLUTIDE IN OBESITY MANAGEMENT

Semaglutide has gained recognition as an effective pharmacological treatment for obesity, including individuals who do not have type 2 diabetes. Its success in promoting weight loss is largely due to its action on the central nervous system, particularly in the areas of the brain that regulate appetite and satiety ^[14,15]. By influencing these pathways, semaglutide helps reduce feelings of hunger, lowers overall caloric intake, and enhances control over eating behaviour. Clinical evidence from the STEP (Semaglutide Treatment Effect in People with Obesity) trials has consistently shown substantial weight loss outcomes, with many participants experiencing reductions exceeding 10% to 15% of their initial body weight when the medication is used over an extended period ^[16,17]. Such a degree of weight loss is considered clinically significant, as it is associated with marked improvements in key health parameters, including reduced cardiovascular risk, better metabolic function, and enhanced quality of life ^[18,19]. Due to its durable efficacy and generally well-tolerated safety profile, semaglutide is becoming a central component of medical obesity treatment, particularly for individuals who do not achieve sufficient results through diet and exercise alone ^[20].

1. APPETITE SUPPRESSION AND WEIGHT LOSS MECHANISMS

Semaglutide helps manage obesity by mimicking a natural hormone called GLP-1, which affects areas of the brain that control appetite. It works by reducing hunger, increasing feelings of fullness, and slowing the movement of food through the stomach. This leads to a lower calorie intake and gradual weight loss. Additionally, it helps regulate blood sugar levels by improving insulin release and reducing glucagon, which may further support appetite control. Additionally, it slows gastric emptying, which prolongs the feeling of fullness after meals ^[21].
The efficacy of semaglutide in promoting weight loss has been well established through the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. In these trials, participants receiving once-weekly semaglutide (2.4 mg) alongside lifestyle interventions achieved substantially greater weight loss compared to those receiving placebo. For instance, in STEP 1, participants experienced an average weight reduction of around 15% of their baseline body weight, with many achieving reductions of 20% or more ^[22,23].

2. IMPACT ON BODY MASS INDEX (BMI) AND FAT MASS

Treatment with semaglutide has been associated with substantial reductions in body mass index (BMI), total body weight, and fat mass. These effects are largely attributed to a pronounced decrease in adipose tissue, especially visceral fat, which is strongly linked to insulin resistance, inflammation, and other components of metabolic syndrome. By acting on appetite-regulating centers in the hypothalamus, semaglutide reduces hunger and caloric intake, leading to consistent and sustained weight loss . Clinical trials, such as the STEP and SELECT studies, have demonstrated that patients receiving semaglutide can achieve an average weight reduction of up to 15–20% of their baseline body weight, which is clinically significant and comparable to outcomes achieved with bariatric surgery ^[24]. The preferential reduction in visceral fat is particularly beneficial, as this type of fat is a major contributor to cardiometabolic risk, including type 2 diabetes, dyslipidemia, and hypertension.

Beyond weight reduction, semaglutide has been shown to improve various markers of cardiometabolic health. These include enhanced glycemic control, lowered blood pressure, improved lipid profiles, and reduced levels of inflammatory markers such as C-reactive protein (CRP). Importantly, the SELECT trial in non-diabetic individuals with obesity and established cardiovascular disease found that semaglutide significantly lowered the risk of major adverse cardiovascular events (MACE), including heart attack and stroke. These findings support the evolving role of semaglutide not only as a weight-loss agent but also as a cardioprotective therapy. Given its robust safety profile, favorable tolerability, and the convenience of once-weekly administration, semaglutide is emerging as a leading pharmacological strategy in the long-term management of obesity and its related complications.

DUAL BENEFITS OF SEMAGLUTIDE

Semaglutide offers a unique advantage in individuals with both type 2 diabetes and obesity by targeting overlapping metabolic pathways ^[25]. Its dual action improves glycemic control while simultaneously promoting significant weight loss. This synergy leads to reductions in insulin resistance, blood pressure, and lipid levels, thereby lowering overall cardiovascular risk.
Beyond clinical measures, semaglutide contributes to meaningful improvements in patients' quality of life ^[26]. Weight loss and better blood sugar control often lead to enhanced physical mobility, reduced fatigue, and improved mental well-being. Patients also report greater satisfaction with their treatment and increased confidence in managing their health. These outcomes highlight the broader impact of semaglutide in promoting long-term health and overall wellness in people living with comorbid diabetes and obesity ^[27]. The combined metabolic benefits make semaglutide especially valuable in managing the complex needs of patients with both conditions.

Cardiovascular and Metabolic Benefits

Semaglutide has demonstrated significant cardiovascular benefits in high-risk patients with type 2 diabetes. The SUSTAIN-6 trial, a major cardiovascular outcome study, showed that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. These findings support semaglutide not only as a glucose-lowering agent but also as a cardioprotective therapy for individuals with type 2 diabetes.

In addition to its glycemic and weight-lowering effects, semaglutide contributes to improvements in several key metabolic parameters ^[28,29,30]. It has been associated with modest but meaningful reductions in systolic blood pressure and improvements in lipid profiles, including decreased LDL cholesterol and triglycerides. Moreover, semaglutide may exert beneficial anti-inflammatory effects by reducing systemic inflammation, which plays a central role in the pathophysiology of obesity and its associated complications. Clinical studies have reported that treatment with semaglutide is associated with significant reductions in inflammatory biomarkers, particularly C-reactive protein (CRP), a well-established marker of chronic low-grade inflammation and cardiovascular risk. This reduction suggests an improvement in the inflammatory profile of patients, potentially contributing to improved endothelial function, reduced atherosclerotic progression, and better insulin sensitivity. When combined with its effects on weight loss, glycemic control, and lipid metabolism, the anti-inflammatory actions of semaglutide further enhance its therapeutic impact. These multifaceted benefits work synergistically to lower the overall cardiovascular risk and improve long-term metabolic health, making semaglutide a valuable component of integrated treatment strategies for patients with obesity and type 2 diabetes.

DOSAGE FORMS AND ADMINISTRATION

Semaglutide is most commonly available as a once-weekly subcutaneous injection, which offers the convenience of infrequent dosing and supports patient adherence. The injectable form is typically started at a low dose and gradually increased to minimize gastrointestinal side effects.
In addition to the injectable form, semaglutide is also available in an oral formulation—the first GLP-1 receptor agonist approved for oral use. This option provides an alternative for patients who prefer not to use injections ^[31]. Oral semaglutide is taken once daily, ideally on an empty stomach with a small amount of water, at least 30 minutes before food or other medications.
Both injectable and oral semaglutide require a stepwise titration approach to improve tolerability and reduce gastrointestinal side effects. The injectable form is usually initiated at 0.25 mg once weekly and increased over several weeks to a maintenance dose of 1 mg or up to 2 mg, depending on the indication ^[32,33]. For oral semaglutide, treatment typically starts at 3 mg daily, with gradual escalation to 7 mg or 14 mg as needed. Individualized dosing based on therapeutic goals and patient response is key to optimizing outcomes ^[34].

SAFETY AND TOLERABILITY

The most frequently reported side effects of semaglutide are gastrointestinal in nature. These include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which are typically mild to moderate in severity. These symptoms are most common during the initial dose-escalation phase and tend to diminish over time as the body adjusts to the medication. Starting with a low dose and gradually increasing it helps improve tolerability.

Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2), due to a potential risk of thyroid C-cell tumors observed in animal studies ^[35]. Caution is also advised in patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy, as worsening of these conditions has been reported in some cases. Additionally, proper hydration and monitoring are recommended, particularly during periods of persistent nausea or vomiting, to prevent dehydration ^[36,37].

EMERGING INDICATIONS AND FUTURE DIRECTIONS OF SEMAGLUTIDE

Semaglutide shows promise in delaying or preventing the progression from prediabetes to type 2 diabetes. Studies have demonstrated that its glucose-lowering and weight-reducing effects can significantly improve insulin sensitivity and glucose tolerance in individuals with prediabetic conditions. This suggests potential for early intervention to reduce the future burden of diabetes.
A number of ongoing clinical trials are exploring expanded uses of semaglutide, including its effects on non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease. Future studies are also assessing long-term cardiovascular outcomes and safety profiles in broader populations, including those without diabetes but with high cardiometabolic risk ^[38]. Research is also focusing on combining semaglutide with other therapeutic agents, such as SGLT-2 inhibitors or newer dual agonists like GLP-1/GIP co-agonists, to enhance clinical benefits. Moreover, advances in pharmacogenomics and personalized medicine may allow for tailored treatment plans that optimize efficacy and minimize side effects based on individual patient profiles. These developments position semaglutide at the forefront of a more holistic and targeted approach to managing metabolic diseases.

CONCLUSION

Semaglutide has emerged as a highly effective therapeutic agent with dual benefits in the management of type 2 diabetes and obesity. Its ability to significantly improve glycemic control, promote substantial weight loss, and provide cardiovascular and metabolic benefits highlights its broad clinical utility ^[39]. The evidence from major clinical trials supports its role not only in disease treatment but also in risk reduction for future complications.

Clinically, semaglutide offers a convenient dosing regimen, good tolerability with proper titration, and proven outcomes in diverse patient populations. It is particularly valuable for individuals with coexisting diabetes and obesity, where its synergistic effects can greatly enhance quality of life and long-term health outcomes. Physicians should consider patient-specific factors, including risk profiles and treatment preferences, when incorporating semaglutide into therapeutic plans.Looking ahead, ongoing research into new indications, combination therapies, and personalized treatment approaches suggests that semaglutide will continue to play a pivotal role in the evolving landscape of metabolic disease management ^[40]. Its expanding potential marks a significant advancement toward more comprehensive and patient-centered care in chronic metabolic conditions

REFERENCES

1. Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open [Internet]. 2022 Sep 19;5(9):e2231982. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486455/
2. Kalra S, Sahay R. A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. Diabetes Therapy. 2020 Jul 28; https://doi.org/10.1007/s13300-020-00894-y
3. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism. 2022 Oct 18;25(1). https://doi.org/10.1111/dom.14863
4. Tilinca M, Tiuca R, Niculas C, Varga A, Tilea I. Future perspectives in diabesity treatment: Semaglutide, a glucagon like peptide 1 receptor agonist (Review). Experimental and Therapeutic Medicine. 2021 Aug 12;22(4). doi:10.3892/etm.2021.
5. Hasanzad M, Sarhangi N,et al. A narrative review of current trends in liraglutide: Insights into the unmet needs in management of type 2 diabetes and obesity. J Diabetes Metab Disord. 2020;19:1863–1872. doi: 10.1007/s40200-020-00619-9.
6. Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent progress in hormone research, . 1973; 29:457–496. doi: 10.1016/b978-0-12-571129-6.50016-6.
7. Meier JJ. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Frontiers in Endocrinology. 2021 Jun 25;12.https://doi.org/10.3389/fendo.2021.645617
8. Meier J. J. (2021). Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Frontiers in endocrinology, 12, 645617. https://doi.org/10.3389/fendo.2021.645617
9. Cercato C, Fonseca FA. Cardiovascular risk and obesity. Diabetol Metabolic Syndrome. 2019;11(74) doi: 10.1186/s13098-019-0468-0.
10. Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44 (Suppl 1):S100–S110. doi: 10.2337/dc21-S008. American Diabetes Association.
11. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: Defining the potential of glucagonlike peptide-1-based therapies. The American journal of medicine, 2011;124 (Suppl):S35–S53. doi: 10.1016/j.amjmed.2010.11.004.
12. Meier JJ, Gethmann A, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452–458. doi: 10.1007/s00125-005-0126-y.
13. American Diabetes Association. 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in  Diabetes—2021. Diabetes Care. 2020 Dec 9;44(Supplement 1):S100–10. https://doi.org/10.2337/dc21-S008
14. Depression in association with severe obesity: changes with weight loss. Dixon JB, Dixon ME, O'Brien PE. Arch Intern Med. 2003;163:2058–2065. doi: 10.1001/archinte.163.17.2058.
15. Ilias Papakonstantinou, Konstantinos Tsioufis, Katsi V. Spotlight on the Mechanism of Action of Semaglutide. Current Issues in Molecular Biology. 2024 Dec 23;46(12):14514–41. https://doi.org/10.3390/cimb46120872
16. Jones, L. A., & Brierley, D. I. (2025). GLP-1 and the Neurobiology of Eating Control: RecentAdvances. Endocrinology, 166(2).https://doi.org/10.1210/endocr/bqae167
17. Wilding JPH, Batterham RL, Calanna S, et al. Once weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
18. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4?mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–1061. doi:10.1002/oby.22
19. Davies MJ, Færch L, Jeppesen OK, et al.; STEP 2 Study Group. Semaglutide 2.4?mg once weekly in adults with overweight or obesity and type 2 diabetes: a randomised, double blind, placebo controlled, phase?3 trial. Lancet. 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0
20. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews [Internet]. 2017 May 10;18(7):715–23. Available from: https://pubmed.ncbi.nlm.nih.gov/28489290/
21. Bhatt DL, et al.; SELECT Study Group. Semaglutide for cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2024;390:1234–1245.
22. Bavry AA, Bhatt DL. Semaglutide Treatment Effect in People With Obesity?– STEP?1. J Am Coll Cardiol. 2021;77(6):772–774. doi:10.1016/j.jacc.2020.12.057
23. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA. 2016 Aug 2;316(5):500. https://doi.org/10.1001/jama.2016.10260
24. Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, Obesity and Metabolism [Internet]. 2022 Oct 28; Available from: https://discovery.ucl.ac.uk/id/eprint/10160305/
25. Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, et al. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes. Circulation. 2019 Nov 12;140(20):1613–22. https://doi.org/10.1161/CIRCULATIONAHA.119.041659
26. Sharma, A., Bhatt, D. L., Calvo, G., Brown, N. J., Zannad, F., & Mentz, R. J. Heart failure event definitions in drug trials in patients with type 2 diabetes. The lancet. Diabetes & endocrinology, 2016,4(4), 294–296. https://doi.org/10.1016/S2213-8587(16)00049-8
27. Drucker D. J. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell metabolism, 2016,24(1), 15–30. https://doi.org/10.1016/j.cmet.2016.06.009
28. Gudibanda, Sandeep; Govardhane, Sharayu; Kaloo, Supriya; Shah, Snehal; Miglani, Vaibhav; Verma, Garima. Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data. Journal of Diabetology 15(4):p 421-428, October-December 2024. doi: 10.4103/jod.jod_129_24
29. Yadav D, Mishra M, Tiwari A, Bisen PS, Goswamy HM, Prasad GBKS. Prevalence of Dyslipidemia and Hypertension in Indian Type 2 Diabetic Patients with Metabolic Syndrome and its Clinical Significance. Osong Public Health and Research Perspectives [Internet]. 2014 Jun 1 [cited 2022 Jul 28];5(3):169–75. Available from: https://www.sciencedirect.com/science/article
30. Tremmel, M., Gerdtham, U. G., Nilsson, P. M., & Saha, S. Economic Burden of Obesity: A Systematic Literature Review. International journal of environmental research and public health, 2017,14(4), 435. https://doi.org/10.3390/ijerph14040435
31. Smith S. C., Jr . Multiple risk factors for cardiovascular disease and diabetes mellitus. The American journal of medicine, 2007,120(3 Suppl 1), S3–S11. https://doi.org/10.1016/j.amjmed.2007.01.002
32. Smits, M. M., & Van Raalte, D. H. Safety of Semaglutide. Frontiers in endocrinology,2021, 12, 645563. https://doi.org/10.3389/fendo.2021.645563
33. Lyseng-Williamson K. A. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features. Clinical drug investigation, 2019,39(8), 805–819. https://doi.org/10.1007/s40261-019-0082
34. American Diabetes Association . Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes care, 2019,42(Suppl 1), S90–S102. https://doi.org/10.2337/dc19-S009
35. Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes, obesity & metabolism [Internet]. 2025 Apr;27 Suppl 2(Suppl 2):66–88. Available from: https://pubmed.ncbi.nlm.nih.gov/40196933/
36. Wright Jr EE, Aroda VR. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate Medicine. 2020 Sep 8;132(sup2):26–36. https://doi.org/10.1080/00325481.2020.1798127
37. Brunton, S. A., & Wysham, C. H. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgraduate medicine, 2020, 132(sup2), 3–14. https://doi.org/10.1080/00325481.2020.1798099
38. Gallwitz, B., & Giorgino, F. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Frontiers in endocrinology, 2021,12, 645507. https://doi.org/10.3389/fendo.2021.645507
39. Laiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., & Karter, A. J. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes care,2019, 42(3), 416–426. https://doi.org/10.2337/dc17-1144
40. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England journal of medicine, 2008,359(15), 1577–1589. https://doi.org/10.1056/NEJMoa0806470